Proposed Collection; Comment Request; Multi-Ethnic Study of Atherosclerosis (Mesa) Event Surveillance, 46640-46641 [E7-16402]
Download as PDF
<![CDATA[
46640
Federal Register / Vol. 72, No. 161 / Tuesday, August 21, 2007 / Notices
Respondents
HIPDB Users Group Survey.
NPDB Matched Response
Survey.
HIPDB Matched Response
Survey.
NPDB Non-User Survey ....
HIPDB Non-User Survey ...
Total ............................
Respondent description
Hours per
response
Total burden
(hours)
57
976
231
390
580
260
55
984
848
904
43
202
432
87
213
341
881
30
411
974
1
1
1
1
1
1
3
3
3
3
3
3
3
3
1
1
1
1
1
1
57
976
231
390
580
260
165
2952
2544
2712
129
606
1296
261
213
341
881
30
411
974
.25
.25
.25
.25
.25
.25
.1
.1
.1
.1
.1
.1
.1
.1
.16
.16
.16
.16
.16
.16
............................................
11,577
........................
18,687
..........................
Dated: August 15, 2007.
Alexandra Huttinger,
Acting Director, Division of Policy Review
and Coordination.
[FR Doc. E7–16371 Filed 8–20–07; 8:45 am]
BILLING CODE 4165–15–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Health Resources and Services
Administration
Council on Graduate Medical
Education; Notice of Meeting
In accordance with section 10(a)(2) of
the Federal Advisory Committee Act
(Public Law 92–463), notice is hereby
given of the following meeting:
rmajette on PROD1PC64 with NOTICES
Total
responses
Other HCEs (Reporting) ....
Other HCEs (Querying) .....
Licensing Boards ...............
Government Hospitals .......
MCOs ................................
Other HCEs .......................
Licensing Boards ...............
Hospitals ............................
MCOs ................................
Other HCEs .......................
Licensing Boards ...............
Hospitals ............................
MCOs ................................
Other HCEs .......................
Licensing Boards ...............
MCOs ................................
Other HCEs .......................
Licensing Boards ...............
MCOs ................................
Other HCEs .......................
Written comments and
recommendations concerning the
proposed information collection should
be sent within 30 days of this notice to
the desk officer for HRSA, either by email to OIRA_submission@omb.eop.gov
or by fax to 202–395–6974. Please direct
all correspondence to the ‘‘attention of
the desk officer for HRSA.’’
Name: Council on Graduate Medical
Education (COGME).
Dates and Times: September 18, 2007, 8:30
a.m.–5:15 p.m.; and September 19, 2007, 8:30
a.m.–3:15 p.m.
Place: Crowne Plaza Silver Spring, 8777
Georgia Avenue, Silver Spring, Maryland
20910.
Status: The Meeting Will Be Open to the
Public.
Agenda: On The Morning Of September 18,
Following The Welcoming Remarks From
The Cogme Chair, the Executive Secretary of
COGME, and Health Resources and Services
VerDate Aug<31>2005
Responses
per
respondent
Number of
respondents
15:08 Aug 20, 2007
Jkt 211001
Administration senior management, there
will be presentations of comments and
thoughts from selected Associations on
COGME’s two draft reports, Enhancing GME
Flexibility and New Paradigms for Physician
Training for Improving Access to Healthcare.
Following Council discussions, at 1:30 p.m.
there will be a breakout of Council members
into the two draft writing groups for further
report revisions. At 3:30 p.m., Barbara Chang,
M.D. and Earl Reisdorff, M.D., the writing
group chairs, will give their reports to the
Council. There will be further discussion on
writing group activities and reports. There
will also be a discussion of further steps for
producing reports.
On September 19, there will be a
presentation on a George Washington
University physician workforce planning
initiative. There will be a panel presentation
of activities of three advisory committees
staffed within the Bureau of Health
Professions; the Advisory Committee on
Primary Care Medicine and Dentistry, the
Advisory Committee on Interdisciplinary,
Community Based Linkages, and the National
Advisory Council on Nurse Education and
Practice. Following will be an overview
presentation on State Physician Workforce/
GME Planning. The Council will conclude
with a discussion of new issues/
identification for future reports.
Agenda items are subject to change as
priorities dictate.
For Further Information Contact: Jerald M.
Katzoff, Executive Secretary, COGME,
Division of Medicine and Dentistry, Bureau
of Health Professions, Parklawn Building,
Room 9A–21, 5600 Fishers Lane, Rockville,
Maryland 20857, Telephone (301) 443–6785.
Dated: August 15, 2007.
Alexandra Huttinger,
Acting Director, Division of Policy Review
and Coordination.
[FR Doc. E7–16373 Filed 8–20–07; 8:45 am]
BILLING CODE 4165–15–P
PO 00000
Frm 00042
Fmt 4703
Sfmt 4703
14.25
244
57.75
97.5
145
65
16.5
295.2
254.4
271.2
12.9
60.6
129.6
26.1
34.1
54.6
141
4.8
76.3
155.8
2,826.1
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Proposed Collection; Comment
Request; Multi-Ethnic Study of
Atherosclerosis (Mesa) Event
Surveillance
SUMMARY: In compliance with the
requirement of Section 3506(c)(2)(A) of
the Paperwork Reduction Act of 1995,
for opportunity for public comment on
proposed data collection projects, the
National Heart, Lung, and Blood
Institute (NHLBI), the National
Institutes of Health (NIH) will publish
periodic summaries of proposed
projects to be submitted to the Office of
Management and Budget (OMB) for
review and approval.
Proposed Collection: Title: MultiEthnic Study of Atherosclerosis (MESA)
Event Surveillance. Type of Information
Request: Renewal (OMB No. 0925–
0493). Need and Use of Information
Collection: The study, MESA, is
identifying and quantifying factors
associated with the presence and
progression of subclinical
cardiovascular disease (CVD)—that is,
atherosclerosis and other forms of CVD
that have not produced signs and
symptoms. The findings provide
important information on subclinical
CVD in individuals of different ethnic
backgrounds and provide information
for studies on new interventions to
prevent CVD. The aspects of the study
that concern direct participant
evaluation received a clinical exemption
from OMB clearance (CE–99–11–08) in
E:\FR\FM\21AUN1.SGM
21AUN1
46641
Federal Register / Vol. 72, No. 161 / Tuesday, August 21, 2007 / Notices
April 2000. OMB clearance is being
sought for the contact of physicians and
participant proxies to obtain
information about clinical CVD events
that participants experience during the
follow-up period. Frequency of
Response: Once per CVD event. Affected
Public: Individuals. Types of
Respondents: Physicians and selected
proxies of individuals recruited for
MESA. The annual reporting burden is
as follows: Estimated Number of
Estimated
number of
respondents
Type of respondents
Respondents: 550; Estimated Number of
Responses per Respondent: 1.0; and
Estimated Total Annual Burden Hours
Requested: 36.7.
There are no capital, operating, or
maintenance costs to report.
Estimated
number of
responses per
respondent
Average
burden hours
per response
Estimated
total annual
burden hours
requested
Physicians ..................................................................................................
Participant proxies .....................................................................................
250
300
1.0
1.0
0.20
0.20
16.7
20
Total ....................................................................................................
550
1.0
0.20
36.7
Request for Comments: Written
comments and/or suggestions from the
public and affected agencies are invited
on one or more of the following points:
(1) Whether the proposed collection of
information will have practical utility;
(2) The accuracy of the agency’s
estimate of burden of the proposed
collection of information, including the
validity of the methodology and
assumptions used; (3) Ways to enhance
the quality, utility, and clarity of the
information to be collected; and (4)
Ways to minimize the burden of
collection of information on those who
are to respond, including the use of
appropriate automated, electronic,
mechanical, or other technological
collection techniques or other forms of
information technology.
To
request more information on the
proposed project or to obtain a copy of
data collection plans and instruments,
contact Dr. Jean Olson, Division of
Prevention and Population Sciences,
NHLBI, NIH, II Rockledge Centre, 6701
Rockledge Drive, Suite 10018, MSC #
7936, Bethesda, MD 20892–7936, or call
non-toll-free number 301–435–0397, or
e-mail your request, including your
address to: olsonj@nhlbi.nih.gov.
Comments Due Date: Comments
regarding this information collection are
best assured of having their full effect if
received within 60 days of the date of
this publication.
FOR FURTHER INFORMATION CONTACT:
rmajette on PROD1PC64 with NOTICES
Dated: August 9, 2007.
Michael Lauer,
Chief, Division of Prevention and Population
Sciences, NHLBI, National Institutes of
Health.
Approved: August 9, 2007.
Suzanne Freeman,
NHLBI Project Clearance Officer, National
Institutes of Health.
[FR Doc. E7–16402 Filed 8–20–07; 8:45 am]
BILLING CODE 4140–01–P
VerDate Aug<31>2005
15:08 Aug 20, 2007
Jkt 211001
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Government-Owned Inventions;
Availability for Licensing
National Institutes of Health,
Public Health Service, HHS.
ACTION: Notice.
AGENCY:
SUMMARY: The inventions listed below
are owned by an agency of the U.S.
Government and are available for
licensing in the U.S. in accordance with
35 U.S.C. 207 to achieve expeditious
commercialization of results of federally
funded research and development.
Foreign patent applications are filed on
selected inventions to extend market
coverage for companies and may also be
available for licensing.
ADDRESSES: Licensing information and
copies of the U.S. patent applications
listed below may be obtained by writing
to the indicated licensing contact at the
Office of Technology Transfer, National
Institutes of Health, 6011 Executive
Boulevard, Suite 325, Rockville,
Maryland 20852–3804; telephone: 301/
496–7057; fax: 301/402–0220. A signed
Confidential Disclosure Agreement will
be required to receive copies of the
patent applications.
Prophylactic Vaccines and Therapeutic
Monoclonal Antibodies Against
Influenza
Description of Technology: This
technology describes development of
H5N1 influenza vaccine candidates in
which mutations have been introduced
to increase affinity of the hemagglutinin
(HA) for the sialic acid receptor found
in humans, which have a different sialic
acid linkage than the corresponding
avian receptor. These mutations could
therefore result in a higher immune
response in vaccines, producing a more
robust response than other H5N1
vaccine candidates that retain their
PO 00000
Frm 00043
Fmt 4703
Sfmt 4703
avian receptor preferences. These
mutations also changed antibodysensitivity of the vaccine candidates.
The H5 modifications can be expressed
from DNA or adenoviral vectors, or the
proteins themselves can be
administered. Additionally, these
mutated HAs can be used to develop
therapeutic monoclonal antibodies. The
technology describes three (3) unique
monoclonal antibodies that react with
wild-type H5, wild-type H5 and mutant
HA equivalently, and the mutant HA,
respectively.
Applications: Prophylactic influenza
vaccine; Therapeutic antibodies.
Inventors: Gary J. Nabel et al. (VRC/
NIAID).
Patent Status: U.S. Patent Application
No. 60/850,761 filed 10 Oct 2006 (HHS
Reference No. E–306–2006/0–US–01).
U.S. Patent Application No. 60/
860,301 filed 20 Nov 2006 (HHS
Reference No. E–306–2006/1–US–01).
U.S. Patent Application No. 60/
920,874 filed 30 Mar 2007 (HHS
Reference No. E–306–2006/2–US–01).
U.S. Patent Application No. 60/
921,669 filed 02 Apr 2007 (HHS
Reference No. E–306–2006/3–US–01).
Development Status: Animal (mouse)
data available.
Licensing Status: Available for
licensing.
Licensing Contact: Susan Ano, Ph.D.;
301/435–5515; anos@mail.nih.gov.
Antiviral Compounds With Broad
Neutralization Capabilities
Description of Technology: The NIH is
pleased to announce as available for
licensing a technology that provides for
novel antiviral compounds effective
against a broad spectrum of viruses. The
compounds utilize soluble
phospholipases, exemplified by PLA2–X
and others, either alone or as a fusion
protein with a viral binding
polypeptide. These compositions are
able to inactivate viruses through
enzymatic degradation of the viral
membrane without affecting target cells
E:\FR\FM\21AUN1.SGM
21AUN1
]]>Agencies
[Federal Register Volume 72, Number 161 (Tuesday, August 21, 2007)]
[Notices]
[Pages 46640-46641]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: E7-16402]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
Proposed Collection; Comment Request; Multi-Ethnic Study of
Atherosclerosis (Mesa) Event Surveillance
SUMMARY: In compliance with the requirement of Section 3506(c)(2)(A) of
the Paperwork Reduction Act of 1995, for opportunity for public comment
on proposed data collection projects, the National Heart, Lung, and
Blood Institute (NHLBI), the National Institutes of Health (NIH) will
publish periodic summaries of proposed projects to be submitted to the
Office of Management and Budget (OMB) for review and approval.
Proposed Collection: Title: Multi-Ethnic Study of Atherosclerosis
(MESA) Event Surveillance. Type of Information Request: Renewal (OMB
No. 0925-0493). Need and Use of Information Collection: The study,
MESA, is identifying and quantifying factors associated with the
presence and progression of subclinical cardiovascular disease (CVD)--
that is, atherosclerosis and other forms of CVD that have not produced
signs and symptoms. The findings provide important information on
subclinical CVD in individuals of different ethnic backgrounds and
provide information for studies on new interventions to prevent CVD.
The aspects of the study that concern direct participant evaluation
received a clinical exemption from OMB clearance (CE-99-11-08) in
[[Page 46641]]
April 2000. OMB clearance is being sought for the contact of physicians
and participant proxies to obtain information about clinical CVD events
that participants experience during the follow-up period. Frequency of
Response: Once per CVD event. Affected Public: Individuals. Types of
Respondents: Physicians and selected proxies of individuals recruited
for MESA. The annual reporting burden is as follows: Estimated Number
of Respondents: 550; Estimated Number of Responses per Respondent: 1.0;
and Estimated Total Annual Burden Hours Requested: 36.7.
There are no capital, operating, or maintenance costs to report.
----------------------------------------------------------------------------------------------------------------
Estimated Estimated
Estimated number of Average total annual
Type of respondents number of responses per burden hours burden hours
respondents respondent per response requested
----------------------------------------------------------------------------------------------------------------
Physicians................................... 250 1.0 0.20 16.7
Participant proxies.......................... 300 1.0 0.20 20
------------------------------------------------------------------
Total.................................... 550 1.0 0.20 36.7
----------------------------------------------------------------------------------------------------------------
Request for Comments: Written comments and/or suggestions from the
public and affected agencies are invited on one or more of the
following points: (1) Whether the proposed collection of information
will have practical utility; (2) The accuracy of the agency's estimate
of burden of the proposed collection of information, including the
validity of the methodology and assumptions used; (3) Ways to enhance
the quality, utility, and clarity of the information to be collected;
and (4) Ways to minimize the burden of collection of information on
those who are to respond, including the use of appropriate automated,
electronic, mechanical, or other technological collection techniques or
other forms of information technology.
FOR FURTHER INFORMATION CONTACT: To request more information on the
proposed project or to obtain a copy of data collection plans and
instruments, contact Dr. Jean Olson, Division of Prevention and
Population Sciences, NHLBI, NIH, II Rockledge Centre, 6701 Rockledge
Drive, Suite 10018, MSC 7936, Bethesda, MD 20892-7936, or
call non-toll-free number 301-435-0397, or e-mail your request,
including your address to: olsonj@nhlbi.nih.gov.
Comments Due Date: Comments regarding this information collection
are best assured of having their full effect if received within 60 days
of the date of this publication.
Dated: August 9, 2007.
Michael Lauer,
Chief, Division of Prevention and Population Sciences, NHLBI, National
Institutes of Health.
Approved: August 9, 2007.
Suzanne Freeman,
NHLBI Project Clearance Officer, National Institutes of Health.
[FR Doc. E7-16402 Filed 8-20-07; 8:45 am]
BILLING CODE 4140-01-P
